(Q35968389)

11 August 2017

1 reference

title

Development of TGF-beta signalling inhibitors for cancer therapy (English)

1 reference

11 August 2017

Jonathan M Yingling

1

1 reference

11 August 2017

Kerry L Blanchard

series ordinal

2

1 reference

11 August 2017

J Scott Sawyer

series ordinal

3

1 reference

11 August 2017

1 December 2004

1 reference

Nature Reviews Drug Discovery

11 August 2017

1 reference

11 August 2017

3

1 reference

11 August 2017

1011-1022

1 reference

11 August 2017

12

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd1580

11 August 2017

0 references

cites work

SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor

1 reference

Disruption of transforming growth factor-beta signaling in ELF beta-spectrin-deficient mice

31 March 2020

1 reference

Mechanisms of TGF-beta signaling from cell membrane to the nucleus

31 March 2020

1 reference

Smad-dependent and Smad-independent pathways in TGF-beta family signalling

31 March 2020

1 reference

Proteins associated with type II bone morphogenetic protein receptor (BMPR-II) and identified by two-dimensional gel electrophoresis and mass spectrometry

31 March 2020

1 reference

TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses

31 March 2020

1 reference

Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1

31 March 2020

1 reference

Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer

31 March 2020

1 reference

TGF-beta signaling: positive and negative effects on tumorigenesis

31 March 2020

1 reference

Targeting the TGF beta signaling network in human neoplasia

31 March 2020

1 reference

TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression.

31 March 2020

1 reference

TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice

31 March 2020

1 reference

Metastasis is driven by sequential elevation of H-ras and Smad2 levels.

31 March 2020

1 reference

Epithelial-mesenchymal transitions in tumour progression

31 March 2020

1 reference

Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines

31 March 2020

1 reference

Snail blocks the cell cycle and confers resistance to cell death

31 March 2020

1 reference

Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis

31 March 2020

1 reference

Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions.

31 March 2020

1 reference

Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration.

31 March 2020

1 reference

Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro

31 March 2020

1 reference

Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition

31 March 2020

1 reference

Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.

31 March 2020

1 reference

Regulation of immune responses by TGF-beta

31 March 2020

1 reference

Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease

31 March 2020

1 reference

Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable

31 March 2020

1 reference

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

31 March 2020

1 reference

Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-beta receptor activity

31 March 2020

1 reference

Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis

31 March 2020

1 reference

PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3.

31 March 2020

1 reference

TLP, a novel modulator of TGF-beta signaling, has opposite effects on Smad2- and Smad3-dependent signaling

31 March 2020

1 reference

Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B)

31 March 2020

1 reference

Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation

31 March 2020

1 reference

Cyclin-dependent kinases regulate the antiproliferative function of Smads.

31 March 2020

1 reference

Itch E3 ligase-mediated regulation of TGF-beta signaling by modulating smad2 phosphorylation

31 March 2020

1 reference

Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription

31 March 2020

1 reference

MEKK-1, a component of the stress (stress-activated protein kinase/c-Jun N-terminal kinase) pathway, can selectively activate Smad2-mediated transcriptional activation in endothelial cells

31 March 2020

1 reference

A central role for the JNK pathway in mediating the antagonistic activity of pro-inflammatory cytokines against transforming growth factor-beta-driven SMAD3/4-specific gene expression.

31 March 2020

1 reference

c-Jun inhibits transforming growth factor beta-mediated transcription by repressing Smad3 transcriptional activity.

31 March 2020

1 reference

JNK regulates autocrine expression of TGF-beta1.

31 March 2020

1 reference

Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells

31 March 2020

1 reference

Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition

31 March 2020

1 reference

Bone morphogenetic protein-7 signals opposing transforming growth factor beta in mesangial cells.

31 March 2020

1 reference

BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury

31 March 2020

1 reference

Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects

31 March 2020

1 reference

TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development

31 March 2020

1 reference

Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer

31 March 2020

1 reference

Increased Malignancy of Neu-Induced Mammary Tumors Overexpressing Active Transforming Growth Factor β1

31 March 2020

1 reference

Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis

31 March 2020

1 reference

Disruption of TGF-β signaling in T cells accelerates atherosclerosis

31 March 2020

1 reference

Genetic analysis of the mammalian transforming growth factor-beta superfamily

31 March 2020

1 reference

TGF-beta/Smad3 signals repress chondrocyte hypertrophic differentiation and are required for maintaining articular cartilage

31 March 2020

1 reference

Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart

31 March 2020

1 reference

Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in TGF-beta(2)-knockout mice

31 March 2020

1 reference

Minimal effects on immune parameters following chronic anti-TGF-beta monoclonal antibody administration to normal mice.

31 March 2020

1 reference

Attenuated type II TGF-beta receptor signalling in human malignant oral keratinocytes induces a less differentiated and more aggressive phenotype that is associated with metastatic dissemination

31 March 2020

1 reference

Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis

31 March 2020

1 reference

Transgenic Mice Expressing a Dominant-Negative Mutant Type II Transforming Growth Factor-β Receptor Exhibit Impaired Mammary Development and Enhanced Mammary Tumor Formation

31 March 2020

1 reference

Conditional inactivation of the TGF-beta type II receptor using Cre:Lox

31 March 2020

1 reference

TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia

31 March 2020

1 reference

Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer

31 March 2020

1 reference

Molecular mechanisms underlying ErbB2/HER2 action in breast cancer

31 March 2020

1 reference

Untangling the ErbB signalling network

31 March 2020

1 reference

Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells

31 March 2020

1 reference

Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility

31 March 2020

1 reference

Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery.

31 March 2020

1 reference

Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat.

31 March 2020

1 reference

Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy

31 March 2020

1 reference

ALK5 inhibition in renal disease

31 March 2020

1 reference

Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain

31 March 2020

1 reference

SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.

31 March 2020

1 reference

Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors

31 March 2020

1 reference

Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain

31 March 2020

1 reference

Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI).

31 March 2020

1 reference

Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5).

31 March 2020

1 reference

Selective inhibitors of type I receptor kinase block cellular transforming growth factor-beta signaling.

31 March 2020

1 reference

Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.

31 March 2020

1 reference

SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo

31 March 2020

1 reference

Phase I clinical trial design in cancer drug development.

31 March 2020

1 reference

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

31 March 2020

1 reference

Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998.

31 March 2020

1 reference

Biomarkers in Drug Discovery and Development: From Target Identification through Drug Marketing

31 March 2020

1 reference

Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?

31 March 2020

1 reference

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

31 March 2020

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

31 March 2020

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

31 March 2020

1 reference

Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy

31 March 2020

1 reference

Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer

31 March 2020

1 reference

The role of transforming growth factor-beta in primary brain tumors

31 March 2020

1 reference

Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines

31 March 2020

1 reference

SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7

31 March 2020

1 reference

Development of anticancer drugs targeting the MAP kinase pathway

31 March 2020

1 reference

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity

31 March 2020

1 reference

Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor

31 March 2020

1 reference

Putting tumours in context

31 March 2020

1 reference

Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death

31 March 2020

1 reference

7 January 2021

Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease

1 reference

7 January 2021

Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene

1 reference

7 January 2021

The TGF beta receptor activation process: an inhibitor- to substrate-binding switch

1 reference

7 January 2021

Identifiers

DOI

10.1038/NRD1580

1 reference

Dimensions Publication ID

11 August 2017

0 references

1 reference